Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Daehwa Pharm Applies for Approval of Anti-Dementia Patch in China
Details : Rivastigmine patch is a class of medications called cholinesterase inhibitors, which is used to manage and treat neurodegenerative disease, specifically dementia, in patients with Alzheimer and Parkinson disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 16, 2023
Lead Product(s) : Rivastigmine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?